Intellectual Property Strategy
Biotech Innovation Is Capital Intensive.
IP Mistakes Are Expensive.
Most small to mid-sized biotech companies operate without dedicated IP management. Strategic IP portfolio discipline often falls between roles.
-
Patent costs escalate with each jurisdiction and renewal cycle
-
Publication pressure risks novelty loss
-
University collaborations complicate inventorship
-
Investors scrutinise chain-of-title and freedom-to-operate
IP requires governance — not just filings.
Patents in Australia and New Zealand
Your IP strategy must be as disciplined as your research, development and regulatory preparation.
Most small to medium biotech companies face the same structural problem:
• No in-house IP manager
• Limited runway
• Complex collaborations
• Escalating patent costs
• Investor scrutiny of ownership and freedom-to-operate
Patent drafting alone is not strategy.
We provide independent, strategic IP advisory services designed specifically for Australian biotech SMEs — ensuring your patent portfolio supports valuation, commercialisation, and regulatory milestones without unnecessary cost escalation.
Protect What Drives Value
IP should strengthen valuation, accelerate investment, and support commercial success — not simply accumulate filings.
If you are building a biotech company and need disciplined, commercially aligned IP strategy, let’s discuss your portfolio.